Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a massive machine-learning analysis shows dynamic, point‑of‑care bleeding risk prediction outperforms static models during PCI; a mechanistic Science Advances paper identifies a YOD1–STAT3 deubiquitination axis driving pathological cardiac hypertrophy and demonstrates targetability; and real‑world multicenter data on transcatheter tricuspid valve replacement (TTVR) show marked TR reduction and symptomatic/end‑organ improvement at 30 days.
Summary
Three impactful cardiology studies stood out today: a massive machine-learning analysis shows dynamic, point‑of‑care bleeding risk prediction outperforms static models during PCI; a mechanistic Science Advances paper identifies a YOD1–STAT3 deubiquitination axis driving pathological cardiac hypertrophy and demonstrates targetability; and real‑world multicenter data on transcatheter tricuspid valve replacement (TTVR) show marked TR reduction and symptomatic/end‑organ improvement at 30 days.
Research Themes
- Dynamic risk prediction and machine learning in interventional cardiology
- Molecular mechanisms of cardiac hypertrophy and novel therapeutic targets
- Structural heart interventions: real-world outcomes of tricuspid therapies
Selected Articles
1. Towards a dynamic model to estimate evolving risk of major bleeding after percutaneous coronary intervention.
Using 2.87 million index PCIs from NCDR CathPCI, tree-based ML models updated bleeding risk at key procedural decision points and improved AUROC from 0.812 to 0.845 versus presentation-only models. Dynamic reclassification identified small subgroups with markedly elevated bleeding risk that would be missed by static estimates, supporting individualized, real-time risk management.
Impact: This work operationalizes dynamic, point-of-care risk prediction during PCI at scale, demonstrating measurable gains over static tools and highlighting actionable reclassification at decision points.
Clinical Implications: Integrate dynamic bleeding risk updates into PCI workflows (access strategy, antithrombotics, closure selection) to minimize in‑hospital bleeding; prioritize prospective implementation and alerting to guide operator choices.
Key Findings
- Training/validation on 2,868,808 index PCIs improved AUROC from 0.812 (presentation variables) to 0.845 (all variables).
- Dynamic reclassification: among 123,712 initially low-risk patients, 14,441 moved to moderate risk (1.4% bleed rate) and 723 to high risk (12.5% bleed rate).
- Updating risk at access choice, pre‑PCI medication, and closure device decisions reduced predictive error versus static, single‑timepoint models.
Methodological Strengths
- Extremely large, contemporary national registry with clear temporal split for training/validation.
- Multiple tree-based ML models evaluated with clinically meaningful reclassification analyses.
Limitations
- Retrospective registry analysis; unmeasured confounding and coding bias possible.
- Outcome limited to in‑hospital bleeding within 72 hours; no prospective clinical deployment or impact assessment.
Future Directions: Prospective trials integrating dynamic models into PCI workflow with clinician-facing decision support; external validation across health systems; assessment of net clinical benefit and calibration drift.
While static risk models may identify key driving risk factors, the dynamic nature of risk requires up-to-date risk information to guide treatment decision making. Bleeding is a complication of percutaneous coronary intervention (PCI), and existing risk models produce only a single risk estimate anchored at a single point in time, despite the dynamic nature of this risk. Using data available from the National Cardiovascular Data Registry (NCDR) CathPCI, we trained 6 different tree-based machine learning models to estimate the risk of bleeding at key decision points: 1) choice of access site, 2) prescription of medication before PCI, and 3) choice of closure device. We began with 3,423,170 PCIs performed between July 2009 through April 2015. We included only index PCIs and removed anyone who had missing data regarding bleeding events or underwent coronary artery bypass grafting during the index admission. We included 2,868,808 PCIs; 2,314,446 (80.7%) before 2014 for training and 554,362 (19.3%) remaining for validation. This study considered all data available from the Registry prior to patient discharge: patient characteristics, coronary anatomy and lesion characterization, laboratory data, past medical history, anti-coagulation, stent type, and closure method categories. The primary outcome was any in-hospital bleeding event within 72 hours after the start of the PCI procedure. Discrimination improved from an area under the receiver operating characteristic curve (AUROC) of 0.812 using only presentation variables to 0.845 using all variables. Among 123,712 patients classified as low risk by the initial model, 14,441 were reclassified as moderate risk (1.4% experienced bleeds), while 723 were reclassified as high risk (12.5% experienced bleeds). Static risk prediction models have more predictive error than those that update risk prediction with newly available data, which provides up-to-date risk prediction for individualized care throughout a hospitalization.
2. Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3.
The study identifies a previously unknown YOD1–STAT3 signaling axis driving pathological cardiac hypertrophy. Cardiomyocyte YOD1 deubiquitinates STAT3 (removing K48 chains from K97), stabilizing and promoting nuclear translocation; genetic deletion or pharmacologic inhibition of YOD1 mitigates Ang II/TAC‑induced hypertrophy and remodeling, nominating YOD1 as a druggable target.
Impact: Revealing a druggable deubiquitinase–transcription factor axis with precise lysine–site mapping provides a mechanistically strong foundation for anti‑hypertrophic therapies.
Clinical Implications: Although preclinical, targeting YOD1 or STAT3 stabilization may offer a novel therapeutic avenue to prevent or reverse pathological hypertrophy and ventricular remodeling, complementing current neurohormonal therapies.
Key Findings
- YOD1 expression is elevated in human hypertrophic myocardium and mouse models.
- Cardiomyocyte-specific YOD1 knockout attenuates Ang II– and TAC–induced hypertrophy.
- YOD1 removes K48-linked ubiquitin chains from STAT3 K97 via its C155 site, stabilizing STAT3 and enhancing nuclear translocation; pharmacologic YOD1 inhibition mitigates ventricular remodeling.
Methodological Strengths
- Multi-layered mechanistic approach: human tissue, mouse genetics (cardiomyocyte-specific knockout), pharmacology, and proteomics.
- Precise site-directed mechanistic mapping (STAT3 K97; YOD1 C155; K48-linked ubiquitin chains).
Limitations
- Preclinical models; translational efficacy and safety in large animals/humans remain untested.
- Specificity and off‑target effects of pharmacologic YOD1 inhibition require further profiling.
Future Directions: Develop selective YOD1 inhibitors with cardiac targeting; evaluate efficacy/safety in large-animal hypertrophy/heart failure models; investigate axis relevance across etiologies (pressure overload, neurohormonal, metabolic).
Identifying previously unknown targets for pathological cardiac hypertrophy and understanding its mechanisms are crucial. Here, we observed that the deubiquitinating enzyme YOD1 was moderately elevated in human hypertrophic myocardium and mouse models. Cardiomyocyte-specific knockout of YOD1 reduced Ang II- and TAC-induced cardiac hypertrophy. Subsequently, we used multiple proteomic analyses to identify and confirm STAT3 as a substrate protein for YOD1. Mechanistically, our findings revealed that the C155 site of YOD1 removes K48-linked ubiquitin chains from K97 on STAT3, stabilizing STAT3 levels and enhancing its nuclear translocation in cardiomyocytes under Ang II stimulation. Notably, inhibiting STAT3 reversed the antihypertrophic effects of YOD1 deficiency in Ang II-challenged mice. In addition, pharmacological inhibition of YOD1 mitigated Ang II-induced pathological ventricular remodeling in mice. This study clarifies the role of YOD1 and introduces a previously unidentified YOD1-STAT3 axis in regulating pathological cardiac hypertrophy, providing valuable insights for drug development targeting this condition.
3. Early Outcomes of Real-World Transcatheter Tricuspid Valve Replacement.
In 176 real‑world TTVR cases across 12 European centers, severe/torrential TR was reduced to mild/none in 98.4% at 30 days, with NYHA improvements and signs of hepatorenal recovery. Baseline conduction disease increased pacemaker implantation risk; right ventricular dysfunction predicted adverse outcomes.
Impact: Provides early, multicenter real‑world evidence supporting commercial TTVR effectiveness and informing patient selection and peri‑procedural risk (conduction, RV function).
Clinical Implications: TTVR can deliver rapid TR reduction with symptomatic and end‑organ improvement; clinicians should screen for conduction abnormalities (anticipate pacing) and carefully assess RV function to stratify risk.
Key Findings
- At 30 days, severe or greater TR was reduced to mild/none in 98.4% (126/128) of evaluable patients.
- NYHA class I/II increased from 20.2% at baseline to 79.7% at 1 month, with signs of improved hepatorenal function.
- Pre-existing conduction disturbances were linked to increased pacemaker implantation; baseline RV dysfunction predicted adverse outcomes.
Methodological Strengths
- Multicenter, consecutive real-world cohort reflecting commercial practice.
- Clinically relevant endpoints (TR grade, NYHA class, end-organ function signals) with short-term follow-up.
Limitations
- Retrospective design without a comparator and limited to 30-day outcomes.
- Incomplete reporting of some laboratory measures and potential selection bias at experienced centers.
Future Directions: Longer-term follow-up with hard endpoints, head-to-head comparisons with repair strategies, and refined selection algorithms incorporating RV function and conduction status.
BACKGROUND: Transcatheter tricuspid valve replacement (TTVR) has been recently approved for the treatment of patients with severe tricuspid regurgitation (TR). Real-world evidence regarding the commercial use of TTVR is lacking. OBJECTIVES: The aim of this study was to investigate the real-world safety and efficacy of the EVOQUE TTVR system in patients with severe TR treated at 12 experienced heart valve centers in 5 European countries. METHODS: Consecutive patients treated with the EVOQUE system since approval in Europe (October 2023 to February 2025) were included in this retrospective analysis. Clinical outcomes were assessed at 30-day follow-up. RESULTS: The study included 176 patients (mean age 77.8 years, 72.0% women, median TRI-SCORE 5 points [IQR: 2 points]). At a median follow-up time of 30 days (IQR: 2 days), severe or greater TR was reduced to mild or none in 126 of 128 patients (98.4%; P < 0.001). NYHA functional class improved from 20.2% (28 of 138) class I or II at baseline to 79.7% (110 of 138; P) at 1 month (P < 0.001), with signs of improved hepatorenal function (estimated glomerular filtration rate 47.0 ± 19.9 mL/min/1.73 m CONCLUSIONS: TR elimination following TTVR in a real-world setting was associated with significant symptom and end-organ functional improvement. Patients with massive or torrential TR were more likely to experience functional improvement. Pre-existing conduction disturbances are associated with increased risk for pacemaker implantation, while baseline right ventricular dysfunction is a strong predictor of adverse clinical outcomes.